Published in Ann Oncol on December 15, 2008
nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov (2012) 4.30
Drug resistance and the role of combination chemotherapy in improving patient outcomes. Int J Breast Cancer (2013) 1.05
Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval. Onco Targets Ther (2011) 1.04
Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates. Proc Natl Acad Sci U S A (2014) 0.94
Clinical Translation of Nanomedicine. Chem Rev (2015) 0.93
Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer. Breast Cancer (Auckl) (2011) 0.89
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life. Drug Des Devel Ther (2015) 0.87
The role of taxanes in triple-negative breast cancer: literature review. Drug Des Devel Ther (2015) 0.86
Albumin-bound paclitaxel in solid tumors: clinical development and future directions. Drug Des Devel Ther (2015) 0.85
Shell-crosslinked knedel-like nanoparticles induce lower immunotoxicity than their non-crosslinked analogs. J Mater Chem B Mater Biol Med (2013) 0.85
Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time? J Drug Deliv (2013) 0.83
Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer. Int J Nanomedicine (2014) 0.82
The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancer. Int J Cancer (2012) 0.82
Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy. Curr Oncol (2012) 0.81
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors. Int J Nanomedicine (2015) 0.80
Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy. J Nanomed Nanotechnol (2013) 0.80
Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis. Oncotarget (2017) 0.79
Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer. Onco Targets Ther (2009) 0.79
The treatment patterns, efficacy, and safety of nab (®)-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis. BMC Cancer (2015) 0.79
Application of albumin-based nanoparticles in the management of cancer. J Mater Sci Mater Med (2015) 0.78
A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases. Cancer Chemother Pharmacol (2013) 0.77
Nanoparticle Based Combination Treatments for Targeting Multiple Hallmarks of Cancer. Int J Nano Stud Technol (2016) 0.75
Excellent biochemical response to polychemotherapy with nab-paclitaxel/gemcitabine in an 82-year-old female with metastatic breast cancer. Case Rep Oncol (2014) 0.75
Weekly nab-Paclitaxel in Metastatic Breast Cancer - Summary and Results of an Expert Panel Discussion. Breast Care (Basel) (2012) 0.75
Novel combinations for the treatment of metastatic breast cancer. Cancers (Basel) (2010) 0.75
Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy? J Cancer Res Clin Oncol (2017) 0.75
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol (2005) 9.70
The multiple faces of caveolae. Nat Rev Mol Cell Biol (2007) 6.85
Local actin polymerization and dynamin recruitment in SV40-induced internalization of caveolae. Science (2002) 5.41
Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res (2006) 4.99
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol (2002) 4.47
Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol (2001) 2.11
Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat (2006) 2.10
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res (1999) 2.06
Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res (1998) 1.95
Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol (2003) 1.81
Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer (2007) 1.66
Potentiation of the antitumoral activity of gemcitabine and paclitaxel in combination on human breast cancer cells. Cancer Biol Ther (2005) 1.65
Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol (1999) 1.43
Caveolin-1 in breast cancer. Cancer Biol Ther (2004) 1.09
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol (2005) 3.50
An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol (2004) 2.45
The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol (2003) 2.32
KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res (2009) 2.02
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer (2007) 1.94
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia (2010) 1.81
Human intestinal intraepithelial lymphocytes are derived from a limited number of T cell clones that utilize multiple V beta T cell receptor genes. J Immunol (1993) 1.71
Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group. Leuk Lymphoma (2008) 1.61
Efficacy of radiotherapy for ovarian ablation: results of a breast intergroup study. Cancer (2004) 1.50
Recommendations for collection and handling of specimens from group breast cancer clinical trials. J Clin Oncol (2008) 1.50
Impact of surgical and pathologic variables in rectal cancer: a United States community and cooperative group report. J Clin Oncol (2001) 1.42
Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial. Cancer (2006) 1.42
Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. J Clin Oncol (2004) 1.41
Cooperative research group members question advertisement. Oncol Nurs Forum (2001) 1.39
Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing. Neurobiol Dis (2005) 1.33
Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177. Int J Radiat Oncol Biol Phys (2006) 1.28
Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. J Clin Oncol (2005) 1.27
Partial purification and properties of tropine dehydrogenase from root cultures of Datura stramonium. Planta Med (1982) 1.19
Isolation and properties of hydroxycinnamate: CoA ligase from lignifying tissue of Forsythia. Eur J Biochem (1974) 1.15
Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy. J Clin Oncol (2003) 1.13
Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial. Cancer (2005) 1.11
Biosynthesis and subcellular distribution of hydrolyzable tannins. Phytochemistry (2001) 1.11
Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51. Int J Radiat Oncol Biol Phys (2006) 1.08
Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J Clin Oncol (2005) 1.07
Importance of baseline mini-mental state examination as a prognostic factor for patients with low-grade glioma. Int J Radiat Oncol Biol Phys (2004) 1.03
Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB). Support Care Cancer (2010) 1.03
Prophylactic cranial irradiation in small-cell lung cancer: findings from a North Central Cancer Treatment Group Pooled Analysis. Ann Oncol (2012) 1.03
Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. Ann Oncol (2006) 1.03
Reduction of coenzyme A thioesters of cinnamic acids with an enzyme preparation from lignifying tissue of Forsythia. FEBS Lett (1975) 1.01
Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results. J Neurooncol (2008) 1.00
Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients. Cancer (2010) 0.98
Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study. Int J Radiat Oncol Biol Phys (2005) 0.97
[Reduction of aromatic acids to aldehydes and alcohols in the cell-free system. 1. Purification and properties of aryl-aldehyde: NADP-oxidoreductase from Neurospora crassa]. Eur J Biochem (1969) 0.97
Adult patients with supratentorial pilocytic astrocytomas: a prospective multicenter clinical trial. Int J Radiat Oncol Biol Phys (2004) 0.96
Formation and reduction of intermediate acyladenylate by aryl-aldehyde. NADP oxidoreductase from Neurospora crassa. Eur J Biochem (1972) 0.89
[Reduction of aromatic acids to aldehydes and alcohols in the cell-free system. 2. Purification and properties of aryl-alcohol: NADP-oxidoreductase from Neurospora crassa]. Eur J Biochem (1969) 0.88
A common TCR beta-chain expressed by CD8+ intestinal mucosa T cells in ulcerative colitis. J Immunol (1996) 0.86
Patient assessment of bowel function during and after pelvic radiotherapy: results of a prospective phase III North Central Cancer Treatment Group clinical trial. J Clin Oncol (2007) 0.86
North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer. Ann Oncol (2009) 0.85
A randomized phase II and pharmacokinetic study of dacarbazine in patients with recurrent glioma. J Neurooncol (2000) 0.85
Reduction of cinnamic acid to cinnamaldehyde and alcohol. Biochem Biophys Res Commun (1968) 0.85
Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633. J Thorac Oncol (2010) 0.84
A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021. Cancer (2008) 0.83
A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group. Urology (2007) 0.83
Gallotannin biosynthesis: beta-glucogallin: hexagalloyl 3-O-galloyltransferase from Rhus typhina leaves. Phytochemistry (2001) 0.83
CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study. Int J Gastrointest Cancer (2002) 0.82
Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer. Am J Clin Oncol (2014) 0.81
A phase II trial of edatrexate, vinblastine, adriamycin, cisplastin, and filgrastim (EVAC/G-CSF) in patients with non-small-cell carcinoma of the lungs: a North Central Cancer Treatment Group Trial. Am J Clin Oncol (2001) 0.80
Biosynthesis of gallotannins: beta-glucogallin-dependent formation of 1,2,3,4,6-pentagalloylglucose by enzymatic galloylation of 1,2,3,6-tetragalloylglucose. Arch Biochem Biophys (1989) 0.80
Biosynthesis of gallotannins. Enzymatic conversion of 1,6-digalloylglucose to 1,2,6-trigalloylglucose. Planta (1988) 0.79
Biosynthesis of gallotannins: formation of polygalloylglucoses by enzymatic acylation of 1,2,3,4,6-penta-O-galloylglucose. Arch Biochem Biophys (1990) 0.79
Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group. Support Care Cancer (2005) 0.78
Comparison of conventional dose and double dose carboplatin in patients receiving cyclophosphamide plus carboplatin for advanced ovarian carcinoma: a North Central Cancer Treatment Group Study. Cancer Invest (2001) 0.76
Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220. Ann Thorac Surg (2014) 0.75
Caring for intraoperative radiation patients. AORN J (1983) 0.75
[Stimulation of delta1-opioid receptors increases the ventricular fibrillation threshold in post-infarct cardiosclerosis: the role of K(ATP)-channels]. Eksp Klin Farmakol (2002) 0.75
Fludarabine therapy in chronic lymphocytic leukemia-associated severe nephrotic syndrome. Haematologica (2000) 0.75
Chemical synthesis of tropoyl coenzyme A. Z Naturforsch C (1980) 0.75
Intraoperative radiation therapy. AORN J (1983) 0.75
[Reduction of aromatic acids to aldehydes and alcohols using enzymes from Neurospora crassa]. Hoppe Seylers Z Physiol Chem (1972) 0.75
[Activation of opioid receptors changes heart resistance to an arrhythmogenic action of ischemia and reperfusion]. Patol Fiziol Eksp Ter (2007) 0.75
Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. J Clin Oncol (2004) 0.75
North Central Cancer Treatment Group--achievements and perspectives. Semin Oncol (2008) 0.75